World J Gastroenterol. 2011 Dec 7;17(45):4987-92.
Lamivudine resistance mutations in patients infected with hepatitis B virus
genotype D.
Source: http://www.ncbi.nlm.nih.gov/pubmed/22174548
Yildiz O, Aygen B, Demirtürk N, Demirdal T, Inan D, Yildirmak T, Kantürk
A, Tütüncü E, Group HB. SourceOrhan Yildiz, Bilgehan Aygen, Department
of Infectious Diseases and Clinical Microbiology, Medical School of Erciyes
University, 38039 Kayseri, Turkey.
Abstract
AIM: To determine the distribution of viral genotypes for primary or
acquired lamivudine resistance.
METHODS: A total of 283 patients with chronic hepatitis B virus (HBV)
infection (245 patients with chronic hepatitis B and 38 inactive hepatitis
B surface antigen carriers) were included in the study. The HBV genotype
was determined by using quantitative real-time polymerase chain reaction
and sequence analysis, and tyrosine-methionine-aspartate-aspartate (YMDD)
motif mutations were determined using the reverse transcriptase
hybridization method.
RESULTS: Lamivudine resistance was determined in a total of 25 (10.7%)
chronic hepatitis B patients. Eight subjects (4%) had primary resistance to
lamivudine, and 17 (53.1%) had secondary resistance to lamivudine. Genotype
D, which was isolated from 267 of the patients with chronic HBV infection,
was the dominant genotype in Turkey.
CONCLUSION: Identification of YMDD motif mutations should have a positive
impact on the selection of proper antiviral medication for patients, even
for those who are nucleoside naïve.
J Med Virol. 2012 Feb;84(2):217-22. doi: 10.1002/jmv.23191.
Pre-existing YMDD mutants in treatment-naïve patients with chronic
hepatitis B are not selected during lamivudine therapy.
Source: http://www.ncbi.nlm.nih.gov/pubmed/22170540
Lee SH, Kim HS, Byun IS, Jeong
SW, Kim SG, Jang JY, Kim YS, Kim BS. SourceDepartment of Internal Medicine,
Soonchunhyang University College of Medicine, Cheonan, Korea.